US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
CA2102780C
(en)
|
1991-05-10 |
2007-01-09 |
Alfred P. Spada |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
JP3560609B2
(ja)
|
1992-11-13 |
2004-09-02 |
イミュネックス・コーポレーション |
Elkリガンドと呼ばれる新規なサイトカイン
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
AU693475B2
(en)
|
1993-10-01 |
1998-07-02 |
Novartis Ag |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
JP4105761B2
(ja)
|
1993-11-19 |
2008-06-25 |
アボット・ラボラトリーズ |
ラパミシン(マクロライド)の半合成類似体免疫調節剤
|
NZ277498A
(en)
|
1993-12-17 |
1998-03-25 |
Novartis Ag |
Rapamycin derivatives
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
AU2096895A
(en)
|
1994-03-07 |
1995-09-25 |
Sugen, Incorporated |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
AU702522B2
(en)
|
1994-04-15 |
1999-02-25 |
Amgen, Inc. |
HEK5, HEK7, HEK8, HEK11, new EPH-like receptor protein tyrosine kinases
|
DE59500788D1
(de)
|
1994-05-03 |
1997-11-20 |
Ciba Geigy Ag |
Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
EP2163546B1
(en)
|
1995-03-30 |
2016-06-01 |
Pfizer Products Inc. |
Quinazoline derivatives
|
ES2150113T3
(es)
|
1995-04-03 |
2000-11-16 |
Novartis Ag |
Derivados de pirazol y procedimientos para la preparacion de los mismos.
|
WO1996033172A1
(en)
|
1995-04-20 |
1996-10-24 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
WO1996041807A1
(en)
|
1995-06-09 |
1996-12-27 |
Novartis Ag |
Rapamycin derivatives
|
US5624677A
(en)
|
1995-06-13 |
1997-04-29 |
Pentech Pharmaceuticals, Inc. |
Controlled release of drugs delivered by sublingual or buccal administration
|
BR9609617B1
(pt)
|
1995-07-06 |
2010-07-27 |
|
derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0780386B1
(en)
|
1995-12-20 |
2002-10-02 |
F. Hoffmann-La Roche Ag |
Matrix metalloprotease inhibitors
|
ES2177925T3
(es)
|
1996-01-23 |
2002-12-16 |
Novartis Ag |
Pirrolopirimidinas y procedimientos para su preparacion.
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6051577A
(en)
|
1996-03-15 |
2000-04-18 |
Novartis Ag |
N-7-heterocyclyl pyrrolo[2,3-D]pyrimidines and the use thereof
|
BR9708640B1
(pt)
|
1996-04-12 |
2013-06-11 |
|
inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo.
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0907642B1
(en)
|
1996-06-24 |
2005-11-02 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
US6207669B1
(en)
|
1996-07-13 |
2001-03-27 |
Glaxo Wellcome Inc. |
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
AU3766897A
(en)
|
1996-07-13 |
1998-02-09 |
Glaxo Group Limited |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
EA199900036A1
(ru)
|
1996-07-18 |
1999-06-24 |
Пфайзер Инк |
Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6153609A
(en)
|
1996-08-23 |
2000-11-28 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
ES2297864T3
(es)
|
1996-08-23 |
2008-05-01 |
Novartis Ag |
Pirrolopirimidinas sustituidas y procesos para su preparacion.
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
ATE291022T1
(de)
|
1996-10-02 |
2005-04-15 |
Novartis Pharma Gmbh |
Pyrimiderivate und verfahren zu ihrer herstellung
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
PT950059E
(pt)
|
1997-01-06 |
2004-10-29 |
Pfizer |
Derivados de sulfona ciclicos
|
TR199901849T2
(xx)
|
1997-02-03 |
2000-02-21 |
Pfizer Products Inc. |
Arils�lfonilamino hidroksamik asit t�revleri.
|
BR9807305A
(pt)
|
1997-02-05 |
2000-05-02 |
Warner Lambert Co |
Pirido [2,3-d] pirimidinas e 4-aminopirimidinas como inibidores de proliferação celular.
|
WO1998034915A1
(en)
|
1997-02-07 |
1998-08-13 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
PL334997A1
(en)
|
1997-02-11 |
2000-03-27 |
Pfizer |
Derivatives or arylosulphonyl-hydroxamic acid
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
WO1999007701A1
(en)
|
1997-08-05 |
1999-02-18 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
ATE263147T1
(de)
|
1997-08-08 |
2004-04-15 |
Pfizer Prod Inc |
Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
|
JP2001520039A
(ja)
|
1997-10-21 |
2001-10-30 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
DE69940808D1
(de)
|
1998-03-04 |
2009-06-10 |
Bristol Myers Squibb Co |
Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
US6395734B1
(en)
|
1998-05-29 |
2002-05-28 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
CA2336848A1
(en)
|
1998-07-10 |
2000-01-20 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
CA2341409A1
(en)
|
1998-08-31 |
2000-03-09 |
Merck And Co., Inc. |
Novel angiogenesis inhibitors
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
CN1221262C
(zh)
|
1999-03-30 |
2005-10-05 |
诺瓦提斯公司 |
治疗炎性疾病的酞嗪衍生物
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
JP4587626B2
(ja)
|
1999-06-07 |
2010-11-24 |
イミュネックス・コーポレーション |
Tekアンタゴニスト
|
PT1196186E
(pt)
|
1999-07-12 |
2008-02-14 |
Genentech Inc |
Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
|
ATE264863T1
(de)
|
1999-08-24 |
2004-05-15 |
Ariad Gene Therapeutics Inc |
28-epirapaloge
|
KR100849151B1
(ko)
|
1999-11-05 |
2008-07-30 |
아스트라제네카 아베 |
Vegf 억제제로서의 퀴나졸린 유도체
|
ES2367007T3
(es)
|
1999-11-24 |
2011-10-27 |
Sugen, Inc. |
Derivados de indolinona ionizables y su uso como ligandos de ptk.
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
WO2001062905A2
(en)
|
2000-02-25 |
2001-08-30 |
Immunex Corporation |
Integrin antagonists
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20050026868A1
(en)
|
2003-07-11 |
2005-02-03 |
Metcalf Chester A. |
Phosphorus-containing macrocycles
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
KR20060052681A
(ko)
|
2003-05-23 |
2006-05-19 |
와이어쓰 |
Gitr 리간드, gitr 리간드-연관 분자, 항체 및그의 용도
|
PL1646634T3
(pl)
|
2003-07-08 |
2009-04-30 |
Novartis Ag |
Zastosowanie rapamycyny i pochodnych rapamycyny w leczeniu utraty kości
|
EP1660126A1
(en)
|
2003-07-11 |
2006-05-31 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
NZ585188A
(en)
|
2003-08-15 |
2011-09-30 |
Novartis Ag |
2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
|
WO2005055808A2
(en)
|
2003-12-02 |
2005-06-23 |
Genzyme Corporation |
Compositions and methods to diagnose and treat lung cancer
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
KR100859891B1
(ko)
|
2004-08-26 |
2008-09-23 |
화이자 인코포레이티드 |
단백질 키나제 억제제로서 거울상이성질체적으로 순수한아미노헤테로아릴 화합물
|
JP2008515984A
(ja)
|
2004-10-13 |
2008-05-15 |
ワイス |
Pi3k阻害剤としての17−ヒドロキシワートマニンの類似体
|
DK1866339T3
(da)
|
2005-03-25 |
2013-09-02 |
Gitr Inc |
GTR-bindende molekyler og anvendelser heraf
|
CN109485727A
(zh)
|
2005-05-09 |
2019-03-19 |
小野药品工业株式会社 |
程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CN101267824A
(zh)
|
2005-09-20 |
2008-09-17 |
辉瑞产品公司 |
使用酪氨酸激酶抑制剂的治疗剂型和方法
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
KR101460816B1
(ko)
|
2006-12-07 |
2014-11-12 |
에프. 호프만-라 로슈 아게 |
포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
|
ES2591281T3
(es)
|
2007-07-12 |
2016-11-25 |
Gitr, Inc. |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
MX338504B
(es)
|
2007-09-12 |
2016-04-20 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinosituro 3-cinasa y agentes quimioterapeuticos, y metodos de uso.
|
US8354528B2
(en)
|
2007-10-25 |
2013-01-15 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
US20110177070A1
(en)
|
2008-07-02 |
2011-07-21 |
Emergent Product Development Seatlle, LLC |
TGF-Beta Antagonist Multi-Target Binding Proteins
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
KR20170119746A
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
JP5856073B2
(ja)
|
2009-12-29 |
2016-02-09 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Ron結合構築体およびその使用方法
|
US10280171B2
(en)
|
2016-05-31 |
2019-05-07 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of PTPN11
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
TW201311689A
(zh)
*
|
2011-08-05 |
2013-03-16 |
必治妥美雅史谷比公司 |
作為因子xia抑制劑之新穎巨環化合物
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
US20150087628A1
(en)
|
2012-04-10 |
2015-03-26 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
WO2014113584A1
(en)
|
2013-01-16 |
2014-07-24 |
Rhode Island Hospital |
Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
|
EP3401314B1
(en)
|
2013-03-15 |
2023-11-08 |
Araxes Pharma LLC |
Covalent inhibitors of kras g12c
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
US9522881B2
(en)
|
2013-04-26 |
2016-12-20 |
Indiana University Research And Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2)
|
WO2015054572A1
(en)
|
2013-10-10 |
2015-04-16 |
Araxes Pharma Llc |
Inhibitors of kras g12c
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
JP6473457B2
(ja)
|
2014-01-17 |
2019-02-20 |
ノバルティス アーゲー |
Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
|
AR102094A1
(es)
|
2014-09-25 |
2017-02-01 |
Araxes Pharma Llc |
Inhibidores de proteínas kras con una mutación g12c
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
EP3283462B1
(en)
|
2015-04-15 |
2020-12-02 |
Araxes Pharma LLC |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
CA2986732A1
(en)
|
2015-05-22 |
2016-12-01 |
Allosta Pharmaceuticals |
Methods to prepare and employ binding site models for modulation of phosphatase activity and selectivity determination
|
WO2016196591A1
(en)
|
2015-06-01 |
2016-12-08 |
Indiana University Research & Technology Corporation |
Protein tyrosine phosphatases or shp2 inhibitors and uses thereof
|
EP3310774B1
(en)
|
2015-06-19 |
2020-04-29 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
EP3325447A1
(en)
|
2015-07-22 |
2018-05-30 |
Araxes Pharma LLC |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
US10858343B2
(en)
|
2015-09-28 |
2020-12-08 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058768A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
US11008372B2
(en)
|
2015-11-07 |
2021-05-18 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
EA038635B9
(ru)
|
2015-11-16 |
2021-10-26 |
Араксис Фарма Ллк |
2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
|
US9932288B2
(en)
|
2015-12-09 |
2018-04-03 |
West Virginia University |
Chemical compound for inhibition of SHP2 function and for use as an anti-cancer agent
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
AU2017266911B2
(en)
|
2016-05-18 |
2021-09-02 |
Array Biopharma, Inc. |
KRas G12C inhibitors
|
EP3464272B1
(en)
|
2016-06-07 |
2021-12-08 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
RU2744988C2
(ru)
|
2016-06-14 |
2021-03-17 |
Новартис Аг |
Соединения и композиции для подавления активности shp2
|
CN116478131A
(zh)
|
2016-07-12 |
2023-07-25 |
锐新医药公司 |
作为变构shp2抑制剂的2,5-双取代型及2,5,6-三取代型3-甲基吡嗪
|
EP3515916B1
(en)
|
2016-09-22 |
2023-06-07 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
CN110036010A
(zh)
|
2016-09-29 |
2019-07-19 |
亚瑞克西斯制药公司 |
Kras g12c突变蛋白的抑制剂
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
TW201819386A
(zh)
|
2016-10-24 |
2018-06-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
BR112019012263A2
(pt)
|
2016-12-15 |
2020-01-28 |
Univ California |
composições e métodos para tratar câncer
|
BR112019012976A2
(pt)
|
2016-12-22 |
2019-12-31 |
Amgen Inc |
inibidores de kras g12c e métodos de uso dos mesmos
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
RU2769132C2
(ru)
|
2017-01-10 |
2022-03-28 |
Новартис Аг |
Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2
|
KR20190111079A
(ko)
|
2017-01-23 |
2019-10-01 |
레볼루션 메디슨즈, 인크. |
알로스테릭 shp2 억제제로서의 이환 화합물
|
BR112019014527A2
(pt)
|
2017-01-23 |
2020-02-27 |
Revolution Medicines, Inc. |
Compostos de piridina como inibidores de shp2 alostéricos
|
EP3573970A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
US11358959B2
(en)
|
2017-01-26 |
2022-06-14 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
EP3573966A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused n-heterocyclic compounds and methods of use thereof
|
WO2018140600A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Fused hetero-hetero bicyclic compounds and methods of use thereof
|
EP3573971A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
KR102317480B1
(ko)
|
2017-03-23 |
2021-10-25 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
SG11201909924VA
(en)
|
2017-05-02 |
2019-11-28 |
Revolution Medicines Inc |
Rapamycin analogs as mtor inhibitors
|
WO2018206539A1
(en)
|
2017-05-11 |
2018-11-15 |
Astrazeneca Ab |
Heteroaryl compounds that inhibit g12c mutant ras proteins
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
EP3630746A1
(en)
|
2017-05-25 |
2020-04-08 |
Araxes Pharma LLC |
Compounds and methods of use thereof for treatment of cancer
|
TW201900633A
(zh)
|
2017-05-25 |
2019-01-01 |
美商亞瑞克西斯製藥公司 |
Kras之共價抑制劑
|
WO2018218069A1
(en)
|
2017-05-25 |
2018-11-29 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant kras, hras or nras
|
WO2018218133A1
(en)
|
2017-05-26 |
2018-11-29 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
|
CN111344017A
(zh)
|
2017-09-07 |
2020-06-26 |
锐新医药公司 |
治疗癌症的shp2抑制剂组合物和方法
|
IL293443A
(en)
|
2017-09-08 |
2022-07-01 |
Amgen Inc |
kras g12c inhibitors and methods of using them
|
CA3074304A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
HUE061599T2
(hu)
|
2017-11-15 |
2023-07-28 |
Mirati Therapeutics Inc |
KRas G12C inhibotorok
|
US10597405B2
(en)
|
2017-12-08 |
2020-03-24 |
Astrazeneca Ab |
Chemical compounds
|
US11426422B2
(en)
|
2018-01-30 |
2022-08-30 |
Research Development Foundation |
SHP2 inhibitors and methods of use thereof
|
CN108113848A
(zh)
|
2018-01-31 |
2018-06-05 |
力迈德医疗(广州)有限公司 |
上肢及头部康复训练机器人
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
JP7335882B2
(ja)
|
2018-02-13 |
2023-08-30 |
ブルーレイ セラピューティクス (シャンハイ) カンパニー,リミティド |
ピリミジン縮合環式化合物及びその製造方法、並びに使用
|
US11044675B2
(en)
|
2018-02-13 |
2021-06-22 |
Idac Holdings, Inc. |
Methods, apparatuses and systems for adaptive uplink power control in a wireless network
|
WO2019165073A1
(en)
|
2018-02-21 |
2019-08-29 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
SG11202006778TA
(en)
|
2018-03-02 |
2020-08-28 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
US20220315586A1
(en)
|
2018-03-21 |
2022-10-06 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
RU2020133727A
(ru)
|
2018-03-21 |
2022-04-21 |
Сучжоу Пухе Биофарма Ко., Лтд. |
Ингибиторы shp2 и их применение
|
US20210069188A1
(en)
|
2018-03-21 |
2021-03-11 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
RS64272B1
(sr)
|
2018-05-01 |
2023-07-31 |
Revolution Medicines Inc |
C40-, c28- i c-32-vezani analozi rapamicina kao inhibitori mtor
|
CN112368289B
(zh)
|
2018-05-01 |
2024-02-20 |
锐新医药公司 |
作为mtor抑制剂的c26-连接的雷帕霉素类似物
|
US10954243B2
(en)
|
2018-05-02 |
2021-03-23 |
Navire Pharma, Inc. |
Substituted heterocyclic inhibitors of PTPN11
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019213516A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
WO2019217307A1
(en)
|
2018-05-07 |
2019-11-14 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
TW202012415A
(zh)
|
2018-05-08 |
2020-04-01 |
瑞典商阿斯特捷利康公司 |
化學化合物
|
CA3099045A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
WO2019233810A1
(en)
|
2018-06-04 |
2019-12-12 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
AU2019284472A1
(en)
|
2018-06-11 |
2020-11-26 |
Amgen Inc. |
KRAS G12C inhibitors for treating cancer
|
WO2020050890A2
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
MA53395A
(fr)
|
2018-07-24 |
2021-06-02 |
Otsuka Pharma Co Ltd |
Composés hétérobicycliques pour inhiber l'activité de shp2
|
EP3829580A1
(en)
|
2018-08-01 |
2021-06-09 |
Araxes Pharma LLC |
Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
|
WO2020033286A1
(en)
|
2018-08-06 |
2020-02-13 |
Purdue Research Foundation |
Novel sesquiterpenoid analogs
|
EP4356973A2
(en)
|
2018-08-10 |
2024-04-24 |
Navire Pharma, Inc. |
6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer
|
CN112119075B
(zh)
|
2018-08-16 |
2024-03-12 |
豪夫迈·罗氏有限公司 |
稠环化合物
|
ES2961253T3
(es)
|
2018-08-31 |
2024-03-11 |
Mirati Therapeutics Inc |
Inhibidores de KRas G12C
|
EP3853233A1
(en)
|
2018-09-18 |
2021-07-28 |
Nikang Therapeutics, Inc. |
Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors
|
CN112839935A
(zh)
|
2018-09-26 |
2021-05-25 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
CA3112322A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Manufacture of compounds and compositions for inhibiting the activity of shp2
|
CA3113379A1
(en)
|
2018-09-29 |
2020-04-02 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of shp2
|
EP3860717A1
(en)
|
2018-10-03 |
2021-08-11 |
Gilead Sciences, Inc. |
Imidozopyrimidine derivatives
|
TW202028183A
(zh)
|
2018-10-10 |
2020-08-01 |
大陸商江蘇豪森藥業集團有限公司 |
含氮雜芳類衍生物調節劑、其製備方法和應用
|
CN111295384B
(zh)
|
2018-10-10 |
2022-08-12 |
江苏豪森药业集团有限公司 |
双环类衍生物抑制剂、其制备方法和应用
|
CN114341124A
(zh)
|
2018-10-17 |
2022-04-12 |
Array生物制药公司 |
蛋白质酪氨酸磷酸酶抑制剂
|
CN111138412B
(zh)
|
2018-11-06 |
2023-09-15 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物及其应用
|
JP2022506887A
(ja)
|
2018-11-07 |
2022-01-17 |
シャンハイ リンジーン バイオファーマ カンパニー リミテッド |
窒素含有縮合複素環系shp2阻害剤化合物、製造方法及び使用
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7454573B2
(ja)
|
2018-11-23 |
2024-03-22 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
インスリン抵抗性を処置するためのshp2阻害剤の使用
|
CN109574871B
(zh)
|
2018-11-23 |
2022-01-04 |
上海交通大学 |
一种乙酰氨基偶氮苯类衍生物及其制备与应用
|
CA3120791A1
(en)
|
2018-11-30 |
2020-06-04 |
Tuojie Biotech (Shanghai) Co., Ltd. |
Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
|
KR20210116479A
(ko)
|
2018-12-21 |
2021-09-27 |
레볼루션 메디슨즈, 인크. |
공동 결합에 참여하는 화합물 및 그의 용도
|
WO2020146613A1
(en)
|
2019-01-10 |
2020-07-16 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitors
|
WO2020156243A1
(zh)
|
2019-01-31 |
2020-08-06 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
CN113316574B
(zh)
|
2019-01-31 |
2024-01-30 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
CA3127286A1
(en)
|
2019-02-12 |
2020-08-20 |
Novartis Ag |
Pharmaceutical combination comprising tno155 and ribociclib
|
AU2020222295B2
(en)
|
2019-02-12 |
2023-04-06 |
Novartis Ag |
Pharmaceutical combination comprising TNO155 and a PD-1 inhibitor
|
EP4249000A3
(en)
|
2019-02-12 |
2023-12-27 |
Novartis AG |
Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
|
CN111647000B
(zh)
|
2019-03-04 |
2021-10-12 |
勤浩医药(苏州)有限公司 |
吡嗪类衍生物及其在抑制shp2中的应用
|
EP3935049A1
(en)
|
2019-03-07 |
2022-01-12 |
Merck Patent GmbH |
Carboxamide-pyrimidine derivatives as shp2 antagonists
|
JP7284830B2
(ja)
|
2019-04-02 |
2023-05-31 |
アレイ バイオファーマ インコーポレイテッド |
タンパク質チロシンホスファターゼ阻害剤
|
JP2022527013A
(ja)
|
2019-04-08 |
2022-05-27 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2拮抗薬としてのピリミジノン誘導体
|
CN112047937B
(zh)
|
2019-06-06 |
2023-04-07 |
劲方医药科技(上海)有限公司 |
四氢吡啶并[3,4-d]嘧啶-2(1H)-酮类化合物,其制法与医药上的用途
|
KR20220061087A
(ko)
|
2019-06-14 |
2022-05-12 |
베이징 셰노젠 파마 그룹 리미티드 |
Shp2 포스파타아제 알로스테릭 억제제
|
CN112110918B
(zh)
|
2019-06-21 |
2023-08-22 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物,其制法与医药上的用途
|
KR20220054285A
(ko)
|
2019-06-28 |
2022-05-02 |
투오지에 바이오텍 (상하이) 컴퍼니 리미티드 |
피리미딘 5 원 질소 헤테로고리형 유도체, 이의 제조 방법 및 이의 약학적 용도
|
CN111704611B
(zh)
|
2019-07-25 |
2022-01-14 |
上海凌达生物医药有限公司 |
一类芳基螺环类shp2抑制剂化合物、制备方法和用途
|
CN112300173B
(zh)
|
2019-07-30 |
2021-10-01 |
上海凌达生物医药有限公司 |
一类含氮多环类化合物、制备方法和用途
|
CN112300194B
(zh)
|
2019-07-30 |
2022-01-14 |
上海凌达生物医药有限公司 |
一类稠环吡啶酮类化合物、制备方法和用途
|
CN114195804A
(zh)
|
2019-07-30 |
2022-03-18 |
上海凌达生物医药有限公司 |
一类哌啶稠环类化合物、制备方法和用途
|
CN112300160A
(zh)
|
2019-08-01 |
2021-02-02 |
上海奕拓医药科技有限责任公司 |
一种螺芳环化合物、其制备及应用
|
EP3772513A1
(en)
|
2019-08-09 |
2021-02-10 |
C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening |
Shp2 inhibitors
|
CN112390818B
(zh)
|
2019-08-12 |
2023-08-22 |
劲方医药科技(上海)有限公司 |
取代的杂芳环并二氢嘧啶酮衍生物,其制法与医药上的用途
|
CN112390788A
(zh)
|
2019-08-13 |
2021-02-23 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
GB201911928D0
(en)
|
2019-08-20 |
2019-10-02 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
CN114127053B
(zh)
|
2019-09-06 |
2023-06-13 |
四川科伦博泰生物医药股份有限公司 |
一种取代吡嗪化合物、其制备方法和用途
|
CN114502165A
(zh)
|
2019-09-23 |
2022-05-13 |
苏州浦合医药科技有限公司 |
Shp2抑制剂及其用途
|
TW202126660A
(zh)
|
2019-09-24 |
2021-07-16 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其製備與使用方法
|
CN112724145A
(zh)
|
2019-10-14 |
2021-04-30 |
杭州雷索药业有限公司 |
用于抑制shp2活性的吡嗪衍生物
|
CN112225734B
(zh)
|
2019-10-25 |
2021-12-07 |
南京瑞捷医药科技有限公司 |
Kras g12c抑制剂及其用途
|
WO2021081752A1
(zh)
|
2019-10-29 |
2021-05-06 |
烟台杰瑞石油装备技术有限公司 |
一种整体式动力端结构的五缸柱塞泵
|
CN112778284B
(zh)
|
2019-11-01 |
2022-04-05 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
US11739074B2
(en)
|
2019-11-04 |
2023-08-29 |
Revolution Medicines, Inc. |
Ras inhibitors
|
AU2020379734A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CA3160142A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
CN112778276A
(zh)
|
2019-11-08 |
2021-05-11 |
南京圣和药业股份有限公司 |
作为shp2抑制剂的化合物及其应用
|
US20230034584A1
(en)
|
2019-12-04 |
2023-02-02 |
Bayer Aktiengesellschaft |
Inhibitors of shp2
|
CN112920183A
(zh)
|
2019-12-06 |
2021-06-08 |
南京圣和药业股份有限公司 |
作为kras-g12c抑制剂的化合物及其应用
|
CN113024544A
(zh)
|
2019-12-09 |
2021-06-25 |
武汉誉祥医药科技有限公司 |
一种含氰基并杂环化合物及其用途
|
WO2021115286A1
(zh)
|
2019-12-10 |
2021-06-17 |
成都倍特药业股份有限公司 |
一种可用作shp2抑制剂的含氮杂原子的六元并五元芳环衍生物
|
WO2021119525A1
(en)
|
2019-12-11 |
2021-06-17 |
Tiaki Therapeutics Inc. |
Shp1 and shp2 inhibitors and their methods of use
|
US20230028414A1
(en)
|
2019-12-16 |
2023-01-26 |
Amgen Inc. |
Dosing regimen of kras g12c inhibitor
|
US20230083431A1
(en)
|
2019-12-18 |
2023-03-16 |
Merck Sharp & Dohme Llc |
Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
CN113651814B
(zh)
|
2019-12-19 |
2022-06-17 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
CN113004269A
(zh)
|
2019-12-19 |
2021-06-22 |
首药控股(北京)有限公司 |
Kras-G12C抑制剂杂环化合物
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
US20230062486A1
(en)
|
2019-12-19 |
2023-03-02 |
Betta Pharmaceuticals Co., Ltd |
Kras g12c inhibitor and pharmaceutical use thereof
|
AU2020408562A1
(en)
|
2019-12-20 |
2022-06-23 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
WO2021120890A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Pyrazolyl derivatives useful as anti-cancer agents
|
CN113024508A
(zh)
|
2019-12-25 |
2021-06-25 |
天津医科大学 |
一类含氮杂环衍生物及其制法和用途
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
CA3162106A1
(en)
|
2019-12-27 |
2021-07-01 |
Yuli Xie |
Spiro ring-containing quinazoline compound
|
CN112094269B
(zh)
|
2020-01-01 |
2021-12-07 |
上海凌达生物医药有限公司 |
一类饱和六元环并杂环类化合物、制备方法和用途
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
TWI770760B
(zh)
|
2020-01-08 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
螺環四氫喹唑啉
|
IL294526A
(en)
|
2020-01-10 |
2022-09-01 |
Incyte Corp |
Tricyclic compounds as kras inhibitors
|
US20230118795A1
(en)
|
2020-01-13 |
2023-04-20 |
Suzhou Zelgen Biopharmaceuticals Co., Ltd. |
Aryl or heteroaryl pyridone or pyrimidine derivative, preparation method and use thereof
|
WO2021143823A1
(zh)
|
2020-01-16 |
2021-07-22 |
浙江海正药业股份有限公司 |
吡啶或嘧啶类衍生物及其制备方法和用途
|
CN114867720A
(zh)
|
2020-01-16 |
2022-08-05 |
浙江海正药业股份有限公司 |
杂芳基类衍生物及其制备方法和用途
|
CN113135910A
(zh)
|
2020-01-19 |
2021-07-20 |
北京诺诚健华医药科技有限公司 |
嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
|
US11530218B2
(en)
|
2020-01-20 |
2022-12-20 |
Incyte Corporation |
Spiro compounds as inhibitors of KRAS
|
WO2021147879A1
(zh)
|
2020-01-21 |
2021-07-29 |
贝达药业股份有限公司 |
Shp2抑制剂及其应用
|
WO2021147965A1
(zh)
|
2020-01-21 |
2021-07-29 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
CN115210232B
(zh)
|
2020-01-22 |
2024-03-01 |
上海齐鲁制药研究中心有限公司 |
吡唑并杂芳环类化合物及其应用
|
EP4093406A4
(en)
|
2020-01-24 |
2024-02-28 |
Taiho Pharmaceutical Co Ltd |
IMPROVEMENT OF THE ANTITUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS IN CANCER
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
CN112159405B
(zh)
|
2020-02-04 |
2021-09-14 |
广州必贝特医药技术有限公司 |
吡啶并嘧啶酮类化合物及其应用
|
EP4129295A4
(en)
|
2020-02-06 |
2023-12-27 |
Wellmarker Bio Co., Ltd. |
PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCERS ASSOCIATED WITH A KRAS MUTATION
|
CN113248521B
(zh)
|
2020-02-11 |
2023-07-18 |
上海和誉生物医药科技有限公司 |
一种k-ras g12c抑制剂及其制备方法和应用
|
WO2021168193A1
(en)
|
2020-02-20 |
2021-08-26 |
Beta Pharma, Inc. |
Pyridopyrimidine derivatives as kras inhibitors
|
CN111265529B
(zh)
|
2020-02-22 |
2021-07-23 |
南京大学 |
蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗银屑病药物中的应用
|
WO2021169990A1
(zh)
|
2020-02-24 |
2021-09-02 |
泰励生物科技(上海)有限公司 |
用于癌症治疗的kras抑制剂
|
CN114845997B
(zh)
|
2020-02-24 |
2024-03-29 |
上海喆邺生物科技有限公司 |
芳香类化合物及其在制备抗肿瘤药物中的应用
|
WO2021173923A1
(en)
|
2020-02-28 |
2021-09-02 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
CN114901663A
(zh)
|
2020-03-02 |
2022-08-12 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
IT202000004849A1
(it)
|
2020-03-06 |
2021-09-06 |
Univ Degli Studi Di Roma “Tor Vergata” |
Peptidi e loro usi
|
CN115298174B
(zh)
|
2020-03-12 |
2023-11-03 |
德昇济医药(无锡)有限公司 |
嘧啶并杂环类化合物及其应用
|
WO2021185233A1
(en)
|
2020-03-17 |
2021-09-23 |
Jacobio Pharmaceuticals Co., Ltd. |
Kras mutant protein inhibitors
|
CN115335379B
(zh)
|
2020-03-25 |
2024-03-29 |
微境生物医药科技(上海)有限公司 |
含螺环的喹唑啉化合物
|
DE102020204310B3
(de)
|
2020-04-02 |
2021-04-01 |
Thyssenkrupp Steel Europe Ag |
Stahl-Fahrzeugrad
|
CN113493440A
(zh)
|
2020-04-03 |
2021-10-12 |
上海翰森生物医药科技有限公司 |
含氮杂芳类衍生物的盐及其晶型
|
CN112142735B
(zh)
|
2020-04-09 |
2021-09-17 |
上海凌达生物医药有限公司 |
一类稠和氰基吡啶类化合物、制备方法和用途
|
US20210355121A1
(en)
|
2020-04-16 |
2021-11-18 |
Incyte Corporation |
Fused tricyclic kras inhibitors
|
CN113527299B
(zh)
|
2020-04-18 |
2023-12-29 |
上海凌达生物医药有限公司 |
一类含氮稠环类化合物、制备方法和用途
|
CN113527293B
(zh)
|
2020-04-20 |
2023-09-08 |
苏州璞正医药有限公司 |
Kras g12c突变蛋白抑制剂及其药物组合物、制备方法和用途
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
US20230242586A1
(en)
|
2020-04-23 |
2023-08-03 |
The Regents Of The University Of California |
Ras inhibitors and uses thereof
|
WO2021215545A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
|
US20230174518A1
(en)
|
2020-04-24 |
2023-06-08 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
WO2021218939A1
(zh)
|
2020-04-28 |
2021-11-04 |
贝达药业股份有限公司 |
稠环化合物及其在医药上的应用
|
CN114516867B
(zh)
|
2020-04-28 |
2023-09-15 |
江南大学 |
一类含氧五元杂环化合物、合成方法、药物组合物及用途
|
WO2021218110A1
(zh)
|
2020-04-29 |
2021-11-04 |
上海凌达生物医药有限公司 |
一类苯并噻唑基联芳基类化合物、制备方法和用途
|
TW202200562A
(zh)
|
2020-04-29 |
2022-01-01 |
中國商北京泰德製藥股份有限公司 |
喹喔啉二酮衍生物作為kras g12c突變蛋白的不可逆抑制劑
|
TW202144349A
(zh)
|
2020-04-30 |
2021-12-01 |
大陸商上海科州藥物研發有限公司 |
作為kras抑制劑的雜環化合物的製備及其應用方法
|
WO2021218755A1
(zh)
|
2020-04-30 |
2021-11-04 |
贝达药业股份有限公司 |
Shp2抑制剂及其组合物和应用
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
CN113683616A
(zh)
|
2020-05-18 |
2021-11-23 |
广州百霆医药科技有限公司 |
Kras g12c突变蛋白抑制剂
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物,其製法與醫藥上的用途
|
KR20230019462A
(ko)
|
2020-06-02 |
2023-02-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
|
AU2021283585A1
(en)
|
2020-06-04 |
2022-11-17 |
Antengene Discovery Limited |
Inhibitors of KRAS G12C protein and uses thereof
|
CN113754653A
(zh)
|
2020-06-05 |
2021-12-07 |
明慧医药(上海)有限公司 |
一种kras g12c抑制剂化合物及其用途
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248090A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
CA3185823A1
(en)
|
2020-06-05 |
2021-12-09 |
Pepsico, Inc. |
Chiller for cooling a beverage
|
WO2021248095A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
CN113754683A
(zh)
|
2020-06-05 |
2021-12-07 |
上海奕拓医药科技有限责任公司 |
同位素取代的螺芳环化合物及其应用
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
JP2023528990A
(ja)
|
2020-06-11 |
2023-07-06 |
貝達薬業股▲ふん▼有限公司 |
Shp2阻害剤、ならびにその組成物および使用
|
WO2021249057A1
(zh)
|
2020-06-12 |
2021-12-16 |
石药集团中奇制药技术(石家庄)有限公司 |
杂环化合物及其用途
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
CN115667239A
(zh)
|
2020-06-22 |
2023-01-31 |
四川科伦博泰生物医药股份有限公司 |
取代吡嗪类化合物,包含其的药物组合物及其用途
|
CN113896710A
(zh)
|
2020-06-22 |
2022-01-07 |
山东轩竹医药科技有限公司 |
Shp2抑制剂及其用途
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
CN115836055A
(zh)
|
2020-06-30 |
2023-03-21 |
益方生物科技(上海)股份有限公司 |
喹唑啉化合物、其制备方法和用途
|
CN113880827A
(zh)
|
2020-07-03 |
2022-01-04 |
苏州闻天医药科技有限公司 |
一种用于抑制krasg12c突变蛋白的化合物及其制备方法和用途
|
CN112823796A
(zh)
|
2020-07-08 |
2021-05-21 |
南京大学 |
蛋白酪氨酸磷酸酶shp2抑制剂在制备治疗骨关节炎药物中的应用
|
CN115916765A
(zh)
|
2020-07-10 |
2023-04-04 |
浙江海正药业股份有限公司 |
吡啶或嘧啶类衍生物及其制备方法和用途
|
CN113929676A
(zh)
|
2020-07-14 |
2022-01-14 |
浙江海正药业股份有限公司 |
吡啶并杂环类衍生物及其制备方法和用途
|
EP4182313A1
(en)
|
2020-07-16 |
2023-05-24 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
US20230339882A1
(en)
|
2020-07-24 |
2023-10-26 |
Betta Pharmaceuticals Co., Ltd. |
Shp2 inhibitor and composition and application thereof
|
CN113980014B
(zh)
|
2020-07-27 |
2023-05-12 |
江苏恒瑞医药股份有限公司 |
氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
|
CN113980032B
(zh)
|
2020-07-27 |
2023-06-16 |
江苏恒瑞医药股份有限公司 |
稠合四环类衍生物、其制备方法及其在医药上的应用
|
WO2022026726A1
(en)
|
2020-07-30 |
2022-02-03 |
Frontier Medicines Corporation |
Processing biophysical screening data and identifying and characterizing protein sites for drug discovery
|
WO2022028346A1
(zh)
|
2020-08-02 |
2022-02-10 |
上海喆邺生物科技有限公司 |
一种芳香类化合物及其在抗肿瘤药物中的应用
|
US20230339976A1
(en)
|
2020-08-04 |
2023-10-26 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
CN114057744A
(zh)
|
2020-08-05 |
2022-02-18 |
百济神州(北京)生物科技有限公司 |
制备kras g12c抑制剂咪唑并三嗪和吡咯并嘧啶衍生物的方法
|
CN114057743A
(zh)
|
2020-08-05 |
2022-02-18 |
百济神州(北京)生物科技有限公司 |
制备kras g12c抑制剂咪唑并三嗪和吡咯并嘧啶衍生物的方法
|
WO2022028492A1
(en)
|
2020-08-05 |
2022-02-10 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
CN116724042A
(zh)
|
2020-08-10 |
2023-09-08 |
深圳微芯生物科技股份有限公司 |
一种杂三环类化合物及其制备方法和应用
|
WO2022040469A1
(en)
|
2020-08-19 |
2022-02-24 |
The Trustees Of The Stevens Institute Of Technology |
Spiro compounds as kras inhibitors
|
CN114075195A
(zh)
|
2020-08-21 |
2022-02-22 |
广东东阳光药业有限公司 |
嘧啶酮衍生物及其在药物中的应用
|
WO2022042331A1
(zh)
|
2020-08-25 |
2022-03-03 |
四川科伦博泰生物医药股份有限公司 |
杂环化合物及其制备方法和用途
|
GB202013321D0
(en)
|
2020-08-26 |
2020-10-07 |
Xeros Ltd |
Treatment process
|
EP4204412A1
(en)
|
2020-08-26 |
2023-07-05 |
InventisBio Co., Ltd. |
Heteroaryl compounds, preparation methods and uses thereof
|
WO2022047093A1
(en)
|
2020-08-28 |
2022-03-03 |
Incyte Corporation |
Vinyl imidazole compounds as inhibitors of kras
|
CN116209438A
(zh)
*
|
2020-09-03 |
2023-06-02 |
锐新医药公司 |
使用sos1抑制剂治疗具有shp2突变的恶性疾病
|
WO2022052895A1
(zh)
|
2020-09-11 |
2022-03-17 |
南京明德新药研发有限公司 |
氮杂环丁烷取代化合物的晶型
|
CN114163457A
(zh)
|
2020-09-11 |
2022-03-11 |
赣江新区博瑞创新医药有限公司 |
嘧啶并五元氮杂环化合物及其用途
|
CA3190944A1
(en)
|
2020-09-11 |
2022-03-17 |
Mirati Therapeutics, Inc. |
Crystalline forms of a kras g12c inhibitor
|
CN116457358A
(zh)
|
2020-09-15 |
2023-07-18 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
CN114195788A
(zh)
|
2020-09-17 |
2022-03-18 |
苏州闻天医药科技有限公司 |
一类四环化合物及其用途
|
WO2022061251A1
(en)
|
2020-09-18 |
2022-03-24 |
Plexxikon Inc. |
Compounds and methods for kras modulation and indications therefor
|
WO2022066646A1
(en)
|
2020-09-22 |
2022-03-31 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
WO2022063190A1
(zh)
|
2020-09-23 |
2022-03-31 |
南京明德新药研发有限公司 |
吡嗪硫联苯基类化合物及其应用
|
MX2023003338A
(es)
|
2020-09-23 |
2023-06-14 |
Erasca Inc |
Piridonas y pirimidonas tricíclicas.
|
WO2022063297A1
(zh)
|
2020-09-27 |
2022-03-31 |
微境生物医药科技(上海)有限公司 |
喹唑啉衍生物及其制备方法和用途
|
US11767320B2
(en)
|
2020-10-02 |
2023-09-26 |
Incyte Corporation |
Bicyclic dione compounds as inhibitors of KRAS
|
EP4225383A1
(en)
|
2020-10-08 |
2023-08-16 |
Kumquat Biosciences Inc. |
Modulators of cell proliferation and uses thereof
|
US20220112204A1
(en)
|
2020-10-14 |
2022-04-14 |
Accutar Biotechnology Inc. |
Substituted dihydropyranopyrimidine compounds as kras inhibitors
|
AU2021362975A1
(en)
|
2020-10-14 |
2023-05-25 |
Ranok Therapeutics (Hangzhou) Co. Ltd. |
Methods and compositions for targeted protein degradation
|
AR123848A1
(es)
|
2020-10-20 |
2023-01-18 |
Amgen Inc |
Compuestos espiro heterocíclicos y métodos de uso
|
WO2022083616A1
(zh)
|
2020-10-21 |
2022-04-28 |
贝达药业股份有限公司 |
一种喹唑啉化合物及其药物组合物
|
WO2022087624A1
(en)
|
2020-10-21 |
2022-04-28 |
Bioardis Llc |
Compounds as ras inhibitors and uses thereof
|
WO2022087371A1
(en)
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel bicyclic compounds
|
WO2022087375A1
(en)
|
2020-10-22 |
2022-04-28 |
Spectrum Pharmaceuticals, Inc. |
Novel heterocyclic compounds
|
CN112402385B
(zh)
|
2020-11-30 |
2022-04-01 |
北京华氏开元医药科技有限公司 |
4-羟甲基-1h-吲哚类化合物药物制剂及其制备方法
|
CN113999226B
(zh)
|
2020-12-22 |
2023-01-06 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
CN112920131A
(zh)
|
2021-03-03 |
2021-06-08 |
天津医科大学 |
一类1,2,4-三氮唑衍生物及其制法和用途
|
CN113248449B
(zh)
|
2021-05-06 |
2022-09-23 |
中国药科大学 |
一种含甲脒的芳基螺环类化合物及其制备方法与应用
|
CN113429405A
(zh)
|
2021-06-10 |
2021-09-24 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
CN113527294A
(zh)
|
2021-08-25 |
2021-10-22 |
都创(上海)医药开发有限公司 |
Mrtx849化合物的晶型及其制备方法和用途
|
CN114057776A
(zh)
|
2021-10-31 |
2022-02-18 |
南京碳硅人工智能生物医药技术研究院有限公司 |
一种具有抗癌活性的嘧啶并哌啶衍生物的新合成方法
|
CN114213417B
(zh)
|
2021-11-16 |
2023-08-22 |
郑州大学 |
吡唑并六元氮杂环类化合物及其合成方法和应用
|